Non-Alcoholic Fatty Liver Disease

Molecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach

Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease

Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease

Prevention of NAFLD in Hispanic Children

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents

Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED

Identification of Liver Fibrosis Biomarkers

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Phase 2b Study of GSK4532990 in Adults With NASH

Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues

Vitamin E Dosing Study

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Direct Versus Indirect Effect of Amino Acids on Hepatokines

Multi-morbidity Screening in People With Type 2 Diabetes and Pre Diabetes

Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

Smartphone App for Non-alcoholic Fatty Liver Disease